Executing the IND-Enabling Studies for Oral PCSK9/LDLR antagonist

Project Summary/Abstract Heart disease has been the leading cause of death in the United States and the world for more than a century, ever since the early 1900s. About 697,000 people die of heart disease in the United States every year (CDC, 2022) and 17.9M death worldwide (WHO 2021). The epidemic burden is enormous; in 2016, cardiovascular

disease (CVD) cost $555 billion in the US alone and by 2035, the cost will skyrocket to $1.1 trillion (CDC, 2023) A high cholesterol level is well-known risk factors for heart disease. Although blood cholesterol can be lowered using a number of marketed drugs, of which statins are the leading drugs, in the US, more than 7M patients who

have high LDL-cholesterol are not sufficiently responsive to statin, and an additional 4M patients are statin intolerance and 1.3M are familial hypercholesteremic (FH). These and other patients will substantially benefit from a different mechanism for treatment of hypercholesterolemia. The long-term goal of this work is to develop

novel orally bioavailable drugs for cholesterol lowering. Our therapeutic target is the protease proprotein convertase subtilisin-like kexin type 9 (PCSK9). PCSK9 controls the degradation of the LDL receptor (LDLR) in the liver and thereby contributes to cholesterol homeostasis. PCSK9 is synthesized as a precursor protein that

undergoes processing. Secreted PCSK9 binds to the LDL-receptor (LDLR) and chaperones it to the degradation pathway. To achieve our goal, we identified a nanomolar orally active small molecule PCSK9/LDLR antagonist (P-21) that showed outstanding potency and safety profile in animal in vivo. The LDL-cholesterol lowering effect

of P-21 is as potent as the marketed monoclonal antibodies. Currently, we have completed bulk of the IND- enabling studies, including the rats GLP toxicology. As part of this direct SBIR Phase II proposal, our goal is to obtain funds that are urgently needed to support the dogs DRF, GLP toxicology, safety pharmacology and FDA

Regulatory Services which are crucial to successfully complete the IND-enabling study to initiate Phase-I clinical trial.